FLT3 and acute myeloid leukemia: Shouval et al. also recently developed a prognostic model for estimating the probability of LFS and OS after ACT in patients with AML in CR1 undergoing transplantation as post‐remission therapy based on age, cytogenetics, and FLT3‐ITD status integrating them into a nomogram (the Auto‐AML score) to be used for the estimation of outcomes after ACT demonstrating that patients with low scores do exceedingly well after ACT.6